Detalhe da pesquisa
1.
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Br J Cancer
; 126(5): 718-725, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34802051
2.
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Blood
; 134(2): 123-133, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862646
3.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 96(2): 226-233, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125764
4.
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Br J Haematol
; 185(3): 492-502, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30828799
5.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol
; 180(6): 821-830, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435979
6.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482145
7.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Blood
; 128(9): 1174-80, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27439911
8.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer
; 123(23): 4617-4630, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817190
9.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Blood
; 126(20): 2284-90, 2015 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384354
10.
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Acta Haematol
; 137(3): 123-131, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28355602
11.
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Lancet Oncol
; 17(11): 1569-1578, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27646843
12.
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.
Biol Blood Marrow Transplant
; 22(9): 1582-1587, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27311969
13.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Biol Blood Marrow Transplant
; 22(2): 380-385, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348890
14.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood
; 124(7): 1047-55, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24904120
15.
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Haematologica
; 101(3): 363-70, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659916
16.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Br J Haematol
; 171(5): 788-97, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26455717
17.
Peripheral-blood stem cells versus bone marrow from unrelated donors.
N Engl J Med
; 367(16): 1487-96, 2012 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23075175
18.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Blood
; 122(18): 3122-8, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24014245
19.
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Biol Blood Marrow Transplant
; 20(3): 295-308, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24141007
20.
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 20(8): 1183-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24769014